Business Context and Reporting Period
This Form 8-K Current Report was filed by DanDrit Biotech USA, Inc. on March 18, 2015, regarding events occurring on March 12 and March 13, 2015. The filing details a material definitive agreement and executive leadership changes involving the Company's wholly owned subsidiary, DanDrit Biotech A/S ("DanDrit Denmark").
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements and employment terms.
- Outgoing CFO Compensation (Robert E. Wolfe): Entitled to accrued salary and expenses through October 31, 2015; up to $4,000 in attorney fees; a $10,000 bonus upon filing of the 2014 Form 10-K; and consulting fees of $150.00 per hour (first 100 hours between May 1 and October 31, 2015 are non-billable).
- Incoming CFO Compensation (Lone Degn): Monthly gross salary of DKK 60,000; reimbursement of reasonable expenses; and a 10% pension contribution based on yearly salary.
Material Changes
The primary material change is the departure of Robert E. Wolfe as Chief Financial Officer of DanDrit Denmark, effective March 12, 2015. Mr. Wolfe will continue as CFO of the parent company through a transition period ending after the filing of the 2014 Annual Report on Form 10-K. Concurrently, Lone Degn was appointed as the new CFO of DanDrit Denmark, effective March 12, 2015.
Outlook, Risks, and Management Commentary
Management anticipates that Ms. Degn will replace Mr. Wolfe as CFO of the parent company following the transition period, subject to board approval and Mr. Wolfe's resignation. The agreements allow for termination in accordance with the Danish Salaried Employees Act. No specific financial risks or contingencies beyond the standard employment terms were disclosed in this filing.
Investor Verification Checklist
- Verify the exact date of the 2014 Form 10-K filing to determine the end of Mr. Wolfe's transition period and the trigger for his $10,000 bonus.
- Confirm the exchange rate impact of Ms. Degn's DKK 60,000 monthly salary on the Company's USD financial statements.
- Review the full text of Exhibits 10.1 and 10.2 for any additional restrictive covenants or termination clauses not summarized in the report.
- Monitor future filings for the formal resignation of Mr. Wolfe as CFO of the parent company and the official appointment of Ms. Degn to that role.